HLA-haploidentical nonmyeloablative stem cell transplantation: Induction to tolerance without passing through mixed chimaerism

Clinical and Laboratory Haematology

Volumn 27, Issue 2, 2005, Pages 139-141

  Ikegame, K ^a   Kawakami, M ^a   Yamagami, T ^b   Maeda, H ^c   Onishi, K ^c   Taniguchi, Y ^a   Fujioka, T ^a   Masuda, T ^a   Kawase, I ^a   Ogawa, Hiroyasu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^c KOBE ROSAI HOSPITAL   (Japan)

Author keywords

Graft vs. host disease; Graft vs. lymphoma effect; HLA haploidentical nonmyeloablative stem cell transplantation; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RANIMUSTINE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DISEASE COURSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; LYMPHOMA, B-CELL; MEDIASTINAL NEOPLASMS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 20244380485     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2005.00675.x     Document Type: Article

References (4)

1. O'Donnell P.V., Luznik L., Jones R.J., Vogelsang G.B., Leffell M.S., Phelps M., Rhubart P., Cowan K., Piantados S. & Fuchs E.J. (2002) Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using post-transplantation cyclophosphamide. Biology of Blood and Marrow Transplantation 8, 377-386.
2. Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G., Varadi G., Kirschbaum M., Ackerstein A., Samuel S., Amar A., Brautbar C., Ben-Tal O., Eldor A. & Or R. (1998) Nonmyeloablative stem cell transplantation and cell therapy an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91, 756-763.
3. Sykes M., Preffer F., McAfee S., Saidman S.L., Weymouth D., Andrews D.M., Colby C., Sackstein R., Sachs D.H. & Spitzer T.R. (1999) Mixed lymphohaemopoietic chimaerlsm and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353, 1755-1759.
4. Tamaki H., Ikegame K., Kawakami M., Fujioka T., Tsuboi A., Oji Y., Oka Y., Sugiyama H., Kawase I. & Ogawa H. (2003) Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 17, 2052-2054.